Population pharmacokinetics of tacrolimus in pediatric patients with systemic‑onset juvenile idiopathic arthritis: Initial dosage recommendations

Wang,Dongdong; Chen,Xiao; Xu,Hong; Li,Zhiping

doi:10.3892/etm.2019.8129

Population pharmacokinetics of tacrolimus in pediatric patients with systemic‑onset juvenile idiopathic arthritis: Initial dosage recommendations

Authors:
- Dongdong Wang
- Xiao Chen
- Hong Xu
- Zhiping Li
View Affiliations

Affiliations: Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China, Department of Nephrology and Rheumatology, Children's Hospital of Fudan University, Shanghai 201102, P.R. China
Published online on: October 25, 2019 https://doi.org/10.3892/etm.2019.8129
Pages: 4653-4660
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pediatric patients with systemic‑onset juvenile idiopathic arthritis (SOJIA) may be treated with tacrolimus. However, the therapeutic range for tacrolimus is narrow with considerable inter‑ and intra‑individual variability, making it difficult to formulate an ideal dosage regimen for personalized treatment. The purpose of the present study was to set up a population pharmacokinetics (PPK) model of tacrolimus treatment for SOJIA to determine the optimal initial dosage. Patients with SOJIA were analyzed using non‑linear mixed‑effects modeling. Different regimens were analyzed using Monte Carlo simulation with concentration profiles. A first‑order absorption and elimination one‑compartment model was selected as the most appropriate model for SOJIA. Based on initial dosage recommendations, the regimen of 0.5 mg every 24 h (q24h) appeared to be most suitable for subjects with a body weight of 5 kg, while the 0.5 mg q12h regimen was most suitable for subjects with a body weight of 15‑25 kg, the 1/0.5 mg q24h regimen was appropriate for the 26‑35 kg group and the 1 mg q12h regimen was suitable for the subjects with a body weight of 36‑50 kg. To the best of our knowledge, the present study established the first PPK model of tacrolimus treatment that may be used for the selection of the initial dose based on body weight of pediatric patients with SOJIA.

View Figures

View References

1	Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonÉ-Paut I, Kostik M, Lovell D, Maritsi D, Nigrovic PA, et al: Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 70:409–419. 2018. View Article : Google Scholar : PubMed/NCBI
2	Cimaz R: Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 15:931–934. 2016. View Article : Google Scholar : PubMed/NCBI
3	Kawai S and Yamamoto K: Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford). 45:441–444. 2006. View Article : Google Scholar : PubMed/NCBI
4	Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M and Sugawara S: Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: A randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 31:243–251. 2004.PubMed/NCBI
5	Chandrasekhara PK, Jayachandran NV, Thomas J, Agrawal S and Narsimulu G: Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol. 28:489–490. 2009. View Article : Google Scholar : PubMed/NCBI
6	Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y, Inoue N and Yachie A: Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. Rheumatology (Oxford). 53:2120–2122. 2014. View Article : Google Scholar : PubMed/NCBI
7	Tanaka H, Tsugawa K, Suzuki K, Oki ES, Nonaka K, Kimura S and Ito E: Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr. 166:1053–1055. 2007. View Article : Google Scholar : PubMed/NCBI
8	Wang D, Chen X and Li Z: Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus. Exp Ther Med. 17:2305–2309. 2019.PubMed/NCBI
9	Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE, Lieberman R, et al: Consensus document: Therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 17:606–614. 1995. View Article : Google Scholar : PubMed/NCBI
10	Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G and Starzl T: Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 29:404–430. 1995. View Article : Google Scholar : PubMed/NCBI
11	Vadcharavivad S, Praisuwan S, Techawathanawanna N, Treyaprasert W and Avihingsanon Y: Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: Comparison with similar data from other populations. J Clin Pharm Ther. 41:310–328. 2016. View Article : Google Scholar : PubMed/NCBI
12	Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R, Marquet P and Rousseau A: Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 51:175–186. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wallin JE, Friberg LE, Fasth A and Staatz CE: Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: New initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit. 31:457–466. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zhu L, Yang J, Zhang Y, Jing Y, Zhang Y and Li G: Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. Xenobiotica. 45:840–846. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yang JW, Liao SS, Zhu LQ, Zhao Y, Zhang Y, Sun XY, Rao W, Qu W, Li WZ and Sun LY: Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther. 53:75–83. 2015. View Article : Google Scholar : PubMed/NCBI
16	Musuamba FT, Guy-Viterbo V, Reding R, Verbeeck RK and Wallemacq P: Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit. 36:54–61. 2014.PubMed/NCBI
17	Lu YX, Su QH, Wu KH, Ren YP, Li L, Zhou TY and Lu W: A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin. 36:281–288. 2015. View Article : Google Scholar : PubMed/NCBI
18	Andreu F, Colom H, Grinyó JM, Torras J, Cruzado JM and Lloberas N: Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. Ther Drug Monit. 37:246–255. 2015. View Article : Google Scholar : PubMed/NCBI
19	Bergmann TK, Hennig S, Barraclough KA, Isbel NM and Staatz CE: Population pharmacokinetics of tacrolimus in adult kidney transplant patients: Impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 36:62–70. 2014.PubMed/NCBI
20	Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, Lee JI, Oh JM and Kim IW: Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol. 114:400–406. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wang DD, Chen X and Li ZP: Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. J Clin Pharm Ther. 44:611–617. 2019. View Article : Google Scholar : PubMed/NCBI
22	Wang D, Chen X, Xu H and Li Z: Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. Xenobiotica. Apr 2;1–8. 2019.doi: 10.1080/00498254.2019.1601791 (Epub ahead of print). View Article : Google Scholar
23	Wang DD, Chen X, Fu M, Zheng QS, Xu H and Li ZP: Model extrapolation to a real-world dataset: Evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica. Jul 3;1–9. 2019.doi: 10.1080/00498254.2019.1631505 (Epub ahead of print). View Article : Google Scholar
24	Wang D, Lu J, Li Q and Li Z: Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. Exp Ther Med. 17:4023–4031. 2019.PubMed/NCBI
25	Anderson BJ and Holford NH: Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 48:303–332. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wang DD, Ye QF, Chen X, Xu H and Li ZP: Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients. Xenobiotica. Aug 14;1–7. 2019.doi: 10.1080/00498254.2019.1651419 (Epub ahead of print). View Article : Google Scholar
27	Wang D, Chen X and Li Z: Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. Oncol Lett. 18:2412–2419. 2019.PubMed/NCBI
28	Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH and Rodvold KA: Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis. 55:303–309. 2006. View Article : Google Scholar : PubMed/NCBI
29	Hahn D, Hodson EM, Willis NS and Craig JC: Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. CD0015332015.PubMed/NCBI
30	Tanaka H, Tsugawa K, Nakahata T, Suzuki K and Ito E: Leukocytapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis. Clin Rheumatol. 26:1014–1016. 2007. View Article : Google Scholar : PubMed/NCBI
31	Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, Henrickson M, Watcher S and Reiff A: Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 32:935–942. 2005.PubMed/NCBI
32	Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, et al: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48:1093–1101. 2003. View Article : Google Scholar : PubMed/NCBI
33	Mok CC, Tong KH, To CH, Siu YP and Au TC: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int. 68:813–817. 2005. View Article : Google Scholar : PubMed/NCBI
34	Kauffman RE and Kearns GL: Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin Pharmacokinet. 23:10–29. 1992. View Article : Google Scholar : PubMed/NCBI
35	Anderson BJ and Holford NH: Tips and traps analyzing pediatric PK data. Paediatr Anaesth. 21:222–237. 2011. View Article : Google Scholar : PubMed/NCBI
36	Holford NH: A size standard for pharmacokinetics. Clin Pharmacokinet. 30:329–332. 1996. View Article : Google Scholar : PubMed/NCBI
37	Savage VM, Deeds EJ and Fontana W: Sizing up allometric scaling theory. PLoS Comput Biol. 4:e10001712008. View Article : Google Scholar : PubMed/NCBI
38	Jacobo-Cabral CO, García-Roca P, Romero-Tejeda EM, Reyes H, Medeiros M, Castañeda-Hernández G and Trocóniz IF: Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: Role of CYP3A5 genotype and formulation. Br J Clin Pharmacol. 80:630–641. 2015. View Article : Google Scholar : PubMed/NCBI